Equillium, Inc. Common Stock
$1.86
-$0.19 (-9.51%)
$1.85Day Range$2.06
Key Statistics
Market Cap
$129.99M
Shares Outstanding
63.4M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 12, 2018
Round Lot
100
Locale
US
Trading Data
Day Open
$2.05
Day High
$2.06
Day Low
$1.85
Volume
770.2K
VWAP
$1.94
Prev Close
$2.05
Transactions
--
Acc. Volume
--
About Equillium, Inc. Common Stock
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
PHARMACEUTICAL PREPARATIONSSIC 283414 employees2223 AVENIDA DE LA PLAYA, LA JOLLA, CA, 92037(858) 412-5302IPO Oct 12, 2018US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001746466
- Composite FIGI
- BBG00LSL8C10
- Share Class FIGI
- BBG00LSL8C29
- Ticker Root
- EQ
- SIC Code
- 2834
About Equillium, Inc. Common Stock (EQ) Stock
Equillium, Inc. Common Stock (EQ) closed the 2026-09-16 session at $1.85, down 9.51% versus the previous close (-0.19). The stock opened at $2.05 and traded between $1.85 and $2.06 during that session. Session trading volume was 770K shares. The volume-weighted average price (VWAP) is $1.94.
Equillium Inc is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders with the mission to develop life-changing therapeutics for patients. It primary goal is to advance EQ504, a novel aryl hydrocarbon receptor, or AhR, modulator, into and through clinical development. The Company operates through a single operating and reportable segment focused on the business of developing novel therapies to treat severe autoimmune and inflammatory disorders, with the mission to develop life-changing therapeutics for patients. The Company manages all business activities on a consolidated basis.
Equillium, Inc. Common Stock has a market capitalization of $130.0 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. EQ is listed on the XNAS exchange. The company employs approximately 14 people. Equillium, Inc. Common Stock is headquartered in LA JOLLA, CA. The recorded listing date is 2018-10-12.
On this page you can find market EQ stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.